EP

EOLO PHARMA

Pharmaceuticals · San Francisco, California, United States · Founded 2017

About

By targeting the body’s energy expenditure pathways, Eolo aims to develop transformative therapies that go beyond traditional weight-loss mechanisms. The lead program, MVD-1, is an oral, first-in-class NCE that targets the body’s natural energy-burning system through a newly druggable pathway: creatine-dependent thermogenesis.

Company details may include data from People Data Labs, licensed CC BY 4.0.